دورية أكاديمية
Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism.
| العنوان: | Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism. |
|---|---|
| المؤلفون: | Castellani LN; Centre for Addition and Mental Health, Toronto, ON M5T1L8, Canada., Costa-Dookhan KA; Centre for Addition and Mental Health, Toronto, ON M5T1L8, Canada.; Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON M5S3K1, Canada., McIntyre WB; Centre for Addition and Mental Health, Toronto, ON M5T1L8, Canada., Wright DC; Human Health and Nutritional Sciences, University of Guelph, Guelph, ON N1G1Y2, Canada., Flowers SA; Department of Pharmacy Practice, University of Illinois, Chicago, IL 60607, USA., Hahn MK; Centre for Addition and Mental Health, Toronto, ON M5T1L8, Canada.; Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON M5S3K1, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON M5T1R8, Canada.; Banting and Best Diabetes Centre, University of Toronto, ON M5G2C4, Canada., Ward KM; Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI 48109, USA. |
| المصدر: | Journal of psychiatry and brain science [J Psychiatr Brain Sci] 2019; Vol. 4. Date of Electronic Publication: 2019 Aug 29. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Qingres Limited Country of Publication: England NLM ID: 101739159 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2398-385X (Electronic) Linking ISSN: 2398385X NLM ISO Abbreviation: J Psychiatr Brain Sci Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [London] : Qingres Limited |
| مستخلص: | Antipsychotic (AP) medications are associated with an increased risk of developing metabolic side effects including weight gain, type 2 diabetes (T2D), dyslipidemia, and hypertension. In the majority of clinical studies, females on APs are noted to gain more weight, and are more likely to be diagnosed with metabolic syndrome when compared to males. However, the data is less clear when comparing sex disparities associated with other specific AP-induced metabolic risk factors. Accumulating evidence has demonstrated a role for AP-induced adipose tissue accumulation as well as whole body glucose dysregulation in male models that is independent of changes in body weight. The purpose of this narrative review is to explore the susceptibility of males and females to changes in adiposity and glucose metabolism across clinical and preclinical models of AP treatment. It is important that future research examining AP-induced metabolic side effects analyzes outcomes by sex to help clarify risk and identify the mechanisms of adverse event development to improve safe prescribing of medications. Competing Interests: CONFLICTS OF INTEREST LNC, WBM, KACD, SAF, KMW, DCW: declare(s) that they have no conflicts of interest; MKH receives consultation fees from Alkermes. |
| References: | Clin Pharmacokinet. 1999 Sep;37(3):177-93. (PMID: 10511917) Cell. 2001 Feb 23;104(4):531-43. (PMID: 11239410) Psychiatry Res. 2002 May 15;110(1):27-37. (PMID: 12007591) J Clin Endocrinol Metab. 2002 Jun;87(6):2918-23. (PMID: 12050274) J Psychopharmacol. 2002 Dec;16(4):291-6. (PMID: 12503827) J Pharmacol Exp Ther. 2003 May;305(2):625-31. (PMID: 12606608) Psychopharmacology (Berl). 2003 May;167(2):115-22. (PMID: 12658526) Pharmacol Biochem Behav. 2003 Apr;75(1):133-40. (PMID: 12759121) Hum Psychopharmacol. 2003 Oct;18(7):551-7. (PMID: 14533137) Clin Pharmacol Ther. 1992 Dec;52(6):643-58. (PMID: 1458773) J Clin Endocrinol Metab. 2003 Dec;88(12):5875-80. (PMID: 14671184) Br J Psychiatry. 2004 Jan;184:58-62. (PMID: 14702228) Life Sci. 2004 Mar 5;74(16):1999-2008. (PMID: 14967195) Behav Brain Res. 2004 Jun 4;152(1):121-7. (PMID: 15135975) J Psychopharmacol. 2004 Jun;18(2):149-55. (PMID: 15260902) Schizophr Bull. 2004;30(2):229-40. (PMID: 15279042) J Clin Psychiatry. 2004 Jun;65(6):864-6. (PMID: 15291666) Am J Psychiatry. 2005 Jan;162(1):118-23. (PMID: 15625209) Diabetes. 2005 Mar;54(3):862-71. (PMID: 15734866) Psychopharmacology (Berl). 2005 Aug;181(1):80-9. (PMID: 15778884) J Clin Psychiatry. 2005 Apr;66(4):504-14. (PMID: 15816794) Psychopharmacology (Berl). 2005 Oct;182(2):220-31. (PMID: 16001110) Behav Brain Res. 2005 Sep 8;163(2):204-11. (PMID: 16009434) Clin Endocrinol (Oxf). 2005 Sep;63(3):280-93. (PMID: 16117815) J Clin Psychopharmacol. 2005 Dec;25(6):570-4. (PMID: 16282840) Obesity (Silver Spring). 2006 Jan;14(1):36-51. (PMID: 16493121) Appetite. 2006 May;46(3):254-62. (PMID: 16551485) Clin Res Cardiol. 2006 Mar;95(3):136-47. (PMID: 16598526) Schizophr Res. 2006 May;84(1):15-9. (PMID: 16626939) J Clin Psychopharmacol. 2006 Apr;26(2):128-34. (PMID: 16633140) Acta Psychiatr Scand. 2006 Jul;114(1):27-35. (PMID: 16774658) Psychopharmacology (Berl). 2006 Sep;187(4):447-54. (PMID: 16783538) Neuropsychopharmacology. 2007 Feb;32(2):289-97. (PMID: 17035934) J Psychopharmacol. 2007 Jun;21(4):405-13. (PMID: 17050655) Psychopharmacology (Berl). 2007 Oct;194(2):221-31. (PMID: 17581744) Nurs Health Sci. 2007 Sep;9(3):177-84. (PMID: 17688475) Neuropsychopharmacology. 2008 Jun;33(7):1633-41. (PMID: 17712347) Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):428-36. (PMID: 17933447) J Sports Med Phys Fitness. 1991 Sep;31(3):351-6. (PMID: 1798304) Braz J Psychiatry. 2007 Dec;29(4):346-9. (PMID: 17992359) Lancet. 2008 Mar 29;371(9618):1085-97. (PMID: 18374841) Schizophr Res. 2008 Aug;103(1-3):94-103. (PMID: 18579346) Diabetes Metab. 2008 Nov;34(5):490-6. (PMID: 18693056) Psychol Med. 2009 May;39(5):801-10. (PMID: 18713488) J Clin Psychopharmacol. 2008 Oct;28(5):494-9. (PMID: 18794643) Diabetologia. 2008 Dec;51(12):2309-17. (PMID: 18843478) Psychoneuroendocrinology. 2009 Jun;34(5):705-12. (PMID: 19131173) Schizophr Res. 2009 Mar;108(1-3):127-33. (PMID: 19157785) Clin Pharmacokinet. 2009;48(3):143-57. (PMID: 19385708) Eur Neuropsychopharmacol. 2009 Sep;19(9):629-35. (PMID: 19467582) Psychopharmacology (Berl). 2009 Sep;206(1):167-76. (PMID: 19572122) Int Clin Psychopharmacol. 2009 Sep;24(5):257-64. (PMID: 19606055) Aust N Z J Psychiatry. 2009 Sep;43(9):812-7. (PMID: 19670054) Schizophr Res. 2009 Nov;115(1):30-40. (PMID: 19679451) Pharmacogenomics. 2009 Sep;10(9):1511-26. (PMID: 19761372) J Clin Endocrinol Metab. 2010 Jan;95(1):118-25. (PMID: 19906788) J Clin Psychopharmacol. 2009 Dec;29(6):576-83. (PMID: 19910724) J Psychopharmacol. 2010 Jul;24(7):1105-14. (PMID: 19965940) Clin Pharmacokinet. 2010;49(2):71-87. (PMID: 20067334) Obesity (Silver Spring). 2010 Aug;18(8):1646-51. (PMID: 20134408) Neuropsychobiology. 2010;61(3):148-61. (PMID: 20173353) Mol Psychiatry. 2011 May;16(5):569-81. (PMID: 20308992) Obesity (Silver Spring). 2010 Dec;18(12):2392-4. (PMID: 20448541) Schizophr Bull. 2012 Jan;38(1):153-66. (PMID: 20494946) Psychopharmacol Bull. 2009;42(4):23-39. (PMID: 20581791) Diabetes. 2010 Oct;59(10):2418-25. (PMID: 20682682) Aust N Z J Psychiatry. 2011 Mar;45(3):193-8. (PMID: 21142850) PLoS One. 2011;6(6):e20571. (PMID: 21695181) Int J Neuropsychopharmacol. 2012 May;15(4):449-57. (PMID: 21733242) Psychopharmacology (Berl). 2012 Feb;219(3):783-94. (PMID: 21748251) Int J Neuropsychopharmacol. 2012 Mar;15(2):163-79. (PMID: 21854679) PLoS One. 2011;6(8):e22662. (PMID: 21857944) Diabet Med. 2012 May;29(5):622-7. (PMID: 22023514) Nat Rev Endocrinol. 2012 Feb 14;8(6):342-51. (PMID: 22330739) J Pediatr Health Care. 2012 Mar;26(2):139-45. (PMID: 22360933) Pharmacopsychiatry. 2012 Sep;45(6):223-8. (PMID: 22426845) Ann Gen Psychiatry. 2012 May 03;11(1):11. (PMID: 22554352) J Psychiatry Neurosci. 2012 Nov;37(6):407-15. (PMID: 22640703) Gastroenterology. 2012 Oct;143(4):913-6.e7. (PMID: 22728514) Exp Clin Endocrinol. 1990 Sep;96(1):25-9. (PMID: 2279523) PLoS One. 2012;7(8):e43244. (PMID: 22905238) Circulation. 2012 Sep 4;126(10):1301-13. (PMID: 22949540) Nutr Diabetes. 2012 Jan 16;2:e26. (PMID: 23154682) Pharmacol Biochem Behav. 2013 Feb;103(4):717-22. (PMID: 23234835) Endocr Rev. 2013 Jun;34(3):309-38. (PMID: 23460719) Diabetes Obes Metab. 2013 Dec;15(12):1128-35. (PMID: 23782571) Diabetes. 2013 Sep;62(9):3232-40. (PMID: 23835329) Int J Neuropsychopharmacol. 2014 Jan;17(1):91-104. (PMID: 23919889) Eur J Pharmacol. 2013 Oct 15;718(1-3):376-82. (PMID: 23973646) Front Neuroendocrinol. 2014 Jan;35(1):8-30. (PMID: 23994581) Eur Neuropsychopharmacol. 2014 Mar;24(3):448-58. (PMID: 24001874) J Clin Psychopharmacol. 2013 Dec;33(6):740-6. (PMID: 24100786) Neuroendocrinology. 2013;98(3):224-32. (PMID: 24135197) Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:170-6. (PMID: 24140931) Eur J Clin Nutr. 2014 Feb;68(2):146-52. (PMID: 24327118) BMC Psychiatry. 2014 Feb 08;14:35. (PMID: 24506972) Lipids Health Dis. 2014 Feb 08;13:29. (PMID: 24507240) PLoS One. 2014 Mar 25;9(3):e93310. (PMID: 24667776) Biomed Res Int. 2014;2014:757461. (PMID: 24734243) PLoS One. 2014 Sep 25;9(9):e107116. (PMID: 25254366) BMC Gastroenterol. 2014 Nov 18;14:189. (PMID: 25407511) Physiol Behav. 2015 Feb;139:202-9. (PMID: 25449399) PLoS One. 2014 Dec 15;9(12):e115225. (PMID: 25506936) Eur Neuropsychopharmacol. 2015 Jun;25(6):923-32. (PMID: 25823694) J Psychopharmacol. 2015 Dec;29(12):1280-9. (PMID: 26378122) Transl Psychiatry. 2015 Oct 06;5:e652. (PMID: 26440540) Dose Response. 2015 Nov 26;13(4):1559325815618915. (PMID: 26740814) JAMA Psychiatry. 2016 Mar;73(3):247-59. (PMID: 26792761) EBioMedicine. 2015 Nov;2(11):1725-34. (PMID: 26870798) J Clin Psychopharmacol. 2016 Apr;36(2):120-4. (PMID: 26872115) Genome Med. 2016 Apr 20;8(1):42. (PMID: 27098727) Biol Pharm Bull. 2016;39(5):754-61. (PMID: 27150145) J Clin Psychopharmacol. 2016 Dec;36(6):580-587. (PMID: 27626286) J Clin Res Pediatr Endocrinol. 2017 Mar 1;9(1):31-38. (PMID: 28008865) Pharmacotherapy. 2017 Mar;37(3):261-267. (PMID: 28035686) Am J Psychiatry. 2017 Jul 1;174(7):686-694. (PMID: 28103712) Int J Psychiatry Clin Pract. 2017 Jun;21(2):112-117. (PMID: 28498089) Psychoneuroendocrinology. 2017 Aug;82:38-45. (PMID: 28500893) Physiol Behav. 2017 Oct 1;179:55-66. (PMID: 28533176) Psychopharmacol Bull. 2017 May 15;47(2):8-21. (PMID: 28626268) J Clin Invest. 2017 Sep 1;127(9):3402-3406. (PMID: 28805659) Front Microbiol. 2017 Sep 22;8:1765. (PMID: 29018410) Int J Neuropsychopharmacol. 2017 Dec 1;20(12):1005-1012. (PMID: 29020342) J Psychiatry Neurosci. 2017 Nov;42(6):424-431. (PMID: 29083297) Mol Metab. 2018 Jan;7:161-170. (PMID: 29122558) Psychoneuroendocrinology. 2018 Feb;88:121-128. (PMID: 29241148) Sci Rep. 2018 Jan 15;8(1):772. (PMID: 29335597) Nature. 2018 Mar 29;555(7698):623-628. (PMID: 29555994) J Pharmacol Exp Ther. 2018 Jun;365(3):526-535. (PMID: 29581153) JCI Insight. 2018 Apr 5;3(7):null. (PMID: 29618657) Schizophr Res. 2018 Nov;201:299-306. (PMID: 29859859) J Child Adolesc Psychopharmacol. 2018 Sep;28(7):474-484. (PMID: 29920116) Psychoneuroendocrinology. 2018 Dec;98:127-130. (PMID: 30142549) Lipids Health Dis. 2018 Sep 15;17(1):218. (PMID: 30219068) Pharmacotherapy. 2019 Feb;39(2):161-170. (PMID: 30620405) Prim Care Diabetes. 2019 Aug;13(4):301-309. (PMID: 30826290) Int J Neuropsychopharmacol. 2019 May 1;22(5):358-369. (PMID: 30854556) Pharmacol Biochem Behav. 1993 May;45(1):51-4. (PMID: 8516372) Ther Drug Monit. 1996 Jun;18(3):254-62. (PMID: 8738764) |
| معلومات مُعتمدة: | KL2 TR002241 United States TR NCATS NIH HHS; L30 GM129789 United States GM NIGMS NIH HHS |
| فهرسة مساهمة: | Keywords: antipsychotics; insulin resistance; metabolic side effects; sex differences; visceral adipose tissue |
| تواريخ الأحداث: | Date Created: 20190927 Latest Revision: 20240420 |
| رمز التحديث: | 20240420 |
| مُعرف محوري في PubMed: | PMC6760310 |
| DOI: | 10.20900/jpbs.20190013 |
| PMID: | 31555747 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2398-385X |
|---|---|
| DOI: | 10.20900/jpbs.20190013 |